Success Metrics

Clinical Success Rate
66.7%

Based on 6 completed trials

Completion Rate
67%(6/9)
Active Trials
0(0%)
Results Posted
150%(9 trials)
Terminated
3(33%)

Phase Distribution

Ph phase_1
1
11%
Ph phase_2
8
89%

Phase Distribution

1

Early Stage

8

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
1(11.1%)
Phase 2Efficacy & side effects
8(88.9%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

6 of 9 finished

Non-Completion Rate

33.3%

3 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(6)
Terminated(3)

Detailed Status

Completed6
Terminated3

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (11.1%)
Phase 28 (88.9%)

Trials by Status

terminated333%
completed667%

Recent Activity

0 active trials
Showing 5 of 9
completedphase_2

Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer

NCT05014776
completedphase_2

Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer

NCT03006302
completedphase_2

Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer

NCT03190265
completedphase_2

GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab

NCT02243371
terminatedphase_1

Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer

NCT02575807
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT05014776Phase 2

Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer

Completed
NCT03006302Phase 2

Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer

Completed
NCT03190265Phase 2

Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer

Completed
NCT02243371Phase 2

GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab

Completed
NCT02575807Phase 1

Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer

Terminated
NCT03122548Phase 2

Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers

Terminated
NCT03175172Phase 2

Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM)

Terminated
NCT02004262Phase 2

Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting

Completed
NCT01417000Phase 2

Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9